arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

CURIS INC

CRIS
$0.85 ▼ -0.16 (-15.63%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
68 Visible periods
29 Metrics
Peer-ranked Benchmarks
Price Chart
24
Health
Poor
Bearish
auto_awesome

Analytical Summary

CURIS INC faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $1.8M
Dividend Yield —
Revenue Growth N/M
Op. Margin None
ROIC -167.3% ↘
FCF / Share $-4.52 ↘
Trailing P/E —
Price / Book 0.4x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

68-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
— —
Net Income Profit after all expenses
$-24.20M
↓ -127.9% —
Operating Margin Operating profit as % of sales
-218.0%
↑ +27.4% 4th
FCF / Share Free cash flow per share
$-4.52
↓ -871.5% —
Long-Term Debt Long-term obligations
$0.00
— —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability ↑
3
Returns ↓
6
Financial Health ↑
39
Cash Quality ↑
93

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 18 years · 68 quarters